Erik Davydov, MD
Internal Medicine · Canyon Country, CANPI 1336173582
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 96.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $5,466 and has fallen 97.5% since, to $138 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $346.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$15K
- AbbVie$437
- Sobi, Inc$56
- Merck$16
What the payments were for
- Consulting fees$3,52023%
- Speaking & faculty fees$9,02559%
- Travel & lodging$1,55010%
- Food & beverage$1,1307%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$15,225 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $81,749 |
| OzempicSemaglutide | 42 | $60,676 |
| TrulicityDulaglutide | 35 | $43,612 |
| FarxigaDapagliflozin Propanediol | 11 | $18,060 |
| Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag | 11 | $17,123 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $6,849 |
| GemtesaVibegron | 12 | $5,489 |
| Atorvastatin Calcium | 412 | $4,578 |
| Metoprolol Succinate | 133 | $2,628 |
| Levothyroxine Sodium | 175 | $2,247 |
| Gabapentin | 48 | $1,980 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 91 | $1,766 |
| Losartan Potassium | 139 | $1,687 |
| Omeprazole | 96 | $1,415 |
| Metformin Hcl | 141 | $1,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14,717 | $81,74968 claims |
| AbbVieSynthroid | $437 | $1,21139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Canyon Country
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.